BridgeBio Oncology Therapeutics (BBOT)
Erin Dominy is an experienced clinical scientist with a strong background in clinical research and operations. Currently serving as the Director of Clinical Science at BBOT since July 2025, Erin previously held the same title at Arvinas from January 2023 to April 2025. Between April 2012 and November 2022, Erin contributed to Clovis Oncology as Associate Director of Clinical Science, among other roles in clinical development and operations. Additional experience includes yoga instruction at Our Yoga Center and Ocean Beach Yoga SF, and serving as Mindfulness Coordinator at Willits Elementary Charter School. Erin's career began at Gilead Sciences and Amgen, with significant roles in clinical research management and coordination, after earning a B.S. in Biopsychology from UC Santa Barbara in 2002.
This person is not in any teams
This person is not in any offices
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.